Alexza's Adasuve crosses US finish line, but distribution limited
This article was originally published in Scrip
Right on schedule, Alexza Pharmaceuticals won a late-afternoon US approval on 21 December to market its inhaled antipsychotic Adasuve (loxapine) to treat agitation associated with schizophrenia or bipolar I disorder in adults, although the drug came with and a black-box warning and must be dispensed through a restricted distribution program, which likely was the trigger for the sell-off of the firm's shares.
You may also be interested in...
Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.